Europe could recommend second biosimilar arthritis drug this week
November 18, 2015 at 05:08 AM EST
LONDON, Nov 18 (Reuters) - Europe could soon gain a second biosimilar antibody drug for rheumatoid arthritis and other autoimmune diseases, with regulators due to decide by Friday whether to recommend South Korean company Samsung Bioepis's copy of Enbrel.